Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Embera NeuroTherapeutics, Inc. is a specialized clinical-stage biopharmaceutical company dedicated to creating and advancing new treatments for a wide array of addictions and substance use disorders (SUDs). Their primary drug candidate, EMB-001, is a unique patented combination of two existing FDA-approved medications, metyrapone and oxazepam. This formulation is engineered to modulate the body's stress response system, which plays a critical role in the cycle of addiction. By targeting the neurobiological mechanisms that drive cravings and relapse, Embera aims to offer effective solutions for individuals grappling with conditions such as cocaine use disorder, tobacco addiction, and potentially other forms of addiction, addressing significant unmet medical needs.
The Boston headquarters manages corporate administration, strategic planning, business development, clinical trial oversight, and investor relations. This location leverages the rich biotech ecosystem for partnerships, talent, and funding.
Situated within BioLabs, a state-of-the-art shared laboratory and office facility tailored for life science startups. This provides access to advanced shared equipment, valuable networking opportunities, and a collaborative R&D environment.
As a clinical-stage biopharmaceutical company, Embera fosters a dynamic, science-driven, and mission-oriented work culture. There is a strong emphasis on collaboration, innovation, and achieving critical clinical milestones to bring new addiction treatments to patients.
The Boston-area headquarters provides crucial access to a dense network of world-class research institutions, a skilled talent pool, venture capital, and pharmaceutical partners essential for a biotech company's growth. The Shreveport research operations are vital for the company's core R&D activities.
While Embera NeuroTherapeutics is primarily based in the United States with corporate functions in Boston, MA, and research operations in Shreveport, LA, its impact is global. The development of its addiction treatments, such as EMB-001, often involves multi-site clinical trials that may include international locations to ensure diverse patient populations and satisfy global regulatory standards. The company actively engages with the international scientific and medical communities through publications, conferences, and collaborations to further the understanding and treatment of substance use disorders worldwide.
c/o BioLabs at The Link, 1350 Boylston Street, Suite B2
Boston
MA
USA
Address: Specific street address for Shreveport research operations not publicly detailed; operations are centered in this region.
The Shreveport site leverages regional research infrastructure, collaborations with local academic institutions, and specialized talent to advance the company's scientific programs and drug development efforts.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Embera NeuroTherapeutics' leadership includes:
Embera NeuroTherapeutics has been backed by several prominent investors over the years, including:
Based on publicly available information and company announcements over the last 12 months, there have been no major new hires or departures at the executive level for Embera NeuroTherapeutics. The leadership team appears to be stable, continuing to guide the company's clinical development programs.
Discover the tools Embera NeuroTherapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Embera NeuroTherapeutics typically uses a standard professional email format common in the biopharmaceutical industry. The most prevalent format combines the first initial of an employee's name with their last name.
[first_initial][last]@emberaneuro.com
Format
rlinke@emberaneuro.com
Example
85%
Success rate
PR Newswire • March 20, 2024
Embera reported positive findings from an investigator-initiated trial where EMB-001 showed a significant reduction in tobacco consumption among patients diagnosed with both tobacco use disorder and schizophrenia spectrum disorders. This study underscores EMB-001's potential to treat addiction in complex patient groups....more
PR Newswire • October 4, 2023
Embera NeuroTherapeutics announced its upcoming presentation on its lead candidate EMB-001 at the European College of Neuropsychopharmacology (ECNP) Congress. The company shared data and insights from its ongoing research into treatments for substance use disorders....more
GlobeNewswire • May 23, 2023
The company marked a significant clinical milestone with the announcement that the last patient had completed their final visit in the Phase 2a study of EMB-001. This trial assessed the drug's efficacy for smoking cessation in individuals diagnosed with schizophrenia....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Embera NeuroTherapeutics, are just a search away.